2-methyl-5-(4-trifluoromethylphenyl)pyridine | 304694-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-methyl-5-(4-trifluoromethylphenyl)pyridine
• 英文别名: 2-Methyl-5-(4-(trifluoromethyl)phenyl)pyridine；2-methyl-5-[4-(trifluoromethyl)phenyl]pyridine
• CAS: 304694-01-7
• 化学式: C₁₃H₁₀F₃N
• 分子量: 237.224
• InChiKey: LKHIWBXRNWJEFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-5-(4-trifluoromethylphenyl)pyridine 、 丙烯酸乙酯 在 palladium diacetate 、 N₂-(3,5-bis(trifluoromethyl)phenyl)-N₆-(2-(isoquinolin-8-yl)phenyl)pyridine-2,6-dicarboxamide 、 C₁₃H₁₀F₆N₄O₂Pd 、 silver carbonate 、 N-乙酰甘氨酸 、 4-二甲氨基吡啶 作用下， 以 丙酮 、 甲苯 为溶剂， 以60 %的产率得到ethyl (E)-3-(2-(6-methylpyridin-3-yl)-5-(trifluoromethyl)phenyl)acrylate
  参考文献：
  名称：

  Remote C−H Olefination of Heterocyclic Biaryls Enabled by Reversibly Bound Templates

  摘要：

  摘要杂环双芳基的远程 C-H 功能化在合成和药物化学中将具有重要意义。通过调整指导原子和目标 C-H 键的几何关系，我们开发出了两种新的催化模板，可以对在元或对位上带有指导杂原子的杂环双芳基中阻碍较大的正 C-H 键进行官能化，从而获得前所未有的位点选择性。模板伴侣的使用还克服了产物抑制作用，并使定向模板具有催化作用。通过对带有各种取代基的杂环双芳基进行烯化反应，证明了这一方案的实用性，克服了传统的立体和电子效应。这些正交-C-H 烯化杂环双芳基具有立体阻碍，通常很难通过芳基-芳基偶联反应制备。

  DOI：

  10.1002/anie.202307581

文献信息

• [EN] 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE 7-PHÉNOXYCHROMANECARBOXYLIQUE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010075200A1

  公开（公告）日：2010-07-01

  Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.

  化合物的化学式I：（I），其中A，A1，R1，R7a，R7b，R8和R10具有规范中给定的含义，是DP2受体抑制剂，在治疗免疫性疾病、过敏性疾病（如哮喘、过敏性鼻炎和特应性皮炎）以及由前列腺素D2（PGD2）介导的其他炎症性疾病的治疗中有用。化合物的化学式I也可能在治疗涉及Th2 T细胞通过IL-4、IL-5和/或IL-13产生的疾病或医疗状况中有用。
• PYRIDINIUM SALT AND PEST CONTROL AGENT
  申请人：Nippon Soda Co., Ltd.

  公开号：US20200275655A1

  公开（公告）日：2020-09-03

  A compound represented by formula (I) or formula (II): wherein, A represents an oxygen atom or a sulfur atom; X 1 represents a halogeno group, a substituted or unsubstituted C 1-6 alkyl group and so on; m represents the number of X 1 and is any integer of 0 to 5; any two of X 1 may be bound together to form a bivalent hydrocarbon group; Y represents a single bond or a substituted or unsubstituted C 2-6 alkenylene group; Q 1 represents a substituted or unsubstituted C 6-10 arylene group or a substituted or unsubstituted 6- to 10-membered heteroarylene group; Q 2 represents a substituted or unsubstituted C 6-10 aryl group or a substituted or unsubstituted 5- to 6-membered heteroaryl group; Z q− represents a counter ion; and q represents a valence of the counter ion and is 1 or 2.

  化合物的化学式为(I)或(II)：其中，A代表氧原子或硫原子；X1代表卤素基团、取代或未取代的C1-6烷基基团等；m代表X1的数量，为0至5的任意整数；任意两个X1可以结合形成二价的碳氢化合物基团；Y代表单键或取代或未取代的C2-6烯基基团；Q1代表取代或未取代的C6-10芳基基团或取代或未取代的6-到10元杂环芳基基团；Q2代表取代或未取代的C6-10芳基基团或取代或未取代的5-到6元杂环芳基基团；Zq-代表计数离子；q代表计数离子的价数，为1或2。
• DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME
  申请人：ABOUABDELLAH Ahmed

  公开号：US20100137329A1

  公开（公告）日：2010-06-03

  The invention relates to a compound having general formula (I): Wherein m, R 1 and R 2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which include in a non-limiting manner, pain, eating disorders, neurological and psychiatric pathologies, among other disorders.

  本发明涉及具有一般式（I）的化合物：其中m、R1和R2如本文所定义。本发明还涉及化合物在治疗学中的应用。更具体地说，本发明的化合物是FAAH酶的抑制剂，因此可用于治疗与FAAH酶相关的各种疾病，包括但不限于疼痛、进食障碍、神经和精神病理等疾病。
• 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES
  申请人：Cook Adam

  公开号：US20120101103A1

  公开（公告）日：2012-04-26

  Compounds of Formula I: (I) in which A, A 1 , R 1 , R 7a , R 7b , R 8 and R 10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D 2 (PGD 2 ). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.

  化合物公式I：（I），其中A，A1，R1，R7a，R7b，R8和R10的含义如规范中所述，是DP2受体抑制剂，可用于治疗免疫性疾病、过敏性疾病（如哮喘、过敏性鼻炎和特应性皮炎）以及通过前列腺素D2（PGD2）介导的其他炎症性疾病的治疗和预防。公式I的化合物还可用于治疗涉及Th2 T细胞通过产生IL-4、IL-5和/或IL-13的疾病或医疗条件。
• 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP2570418A2

  公开（公告）日：2013-03-20

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group -OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and -(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.

  本发明提供了一种由以下通式表示的 2,3-二氢-6-硝基咪唑并[2,1-b]恶唑化合物： 其中R1代表氢原子或C1-C6烷基，n代表0至6的整数，R2代表基团-OR3或类似基团，R3代表氢原子、C1-C6烷基或类似基团，或者R1和-(CH2)nR2可以通过氮原子与相邻的碳原子相互结合，从而形成通式(H)代表的螺环： 其中 R41 为氢、C1-C6 烷基或类似基团。本化合物对结核分枝杆菌、多重耐药结核分枝杆菌和非典型耐酸菌有很好的杀菌作用。